A single dose of mirtazapine modulates neural responses to emotional faces in healthy people - PubMed (original) (raw)

Randomized Controlled Trial

. 2010 Dec;212(4):625-34.

doi: 10.1007/s00213-010-1983-8. Epub 2010 Sep 1.

Affiliations

• PMID: 20809213
• DOI: 10.1007/s00213-010-1983-8

Randomized Controlled Trial

A single dose of mirtazapine modulates neural responses to emotional faces in healthy people

Nancy B Rawlings et al. Psychopharmacology (Berl). 2010 Dec.

Abstract

Rationale: Single-dose administration of selective serotonin and noradrenaline reuptake blockers has been shown to alter emotional processing in both behavioral and fMRI studies in healthy volunteers. Mirtazapine is a clinically established antidepressant with different pharmacological actions from monoamine reuptake inhibitors, involving blockade of noradrenaline α(2)-adrenoceptors and multiple 5-HT receptor subtypes. The aim of this study was to investigate the effect of a single dose of mirtazapine on the neural processing of emotional faces in healthy volunteers.

Methods: Twenty-eight participants were randomized to receive either a single dose of mirtazapine (15 mg) or placebo. Two hours later, participants underwent an fMRI scan, in which they classified fearful and happy faces on the basis of gender. Mood and subjective experience were also measured.

Results: Whole-brain analysis showed significant group × emotion interactions in a right amygdala-hippocampal region and left fronto-striatal cortex. Post hoc analyses revealed significantly reduced activation to fear and greater activation to happy faces in both regions under mirtazapine.

Conclusions: Our findings indicate that a single dose of mirtazapine modulates neural activity to affective stimuli. Mirtazapine was found to decrease neural responses to fear and increase responses to happy facial expressions in regions implicated in the processing of emotional faces. These effects may be important for our understanding of the neural mechanisms of antidepressant action in anxiety and depression.

PubMed Disclaimer

Similar articles

• Early effects of mirtazapine on emotional processing.
  Arnone D, Horder J, Cowen PJ, Harmer CJ. Arnone D, et al. Psychopharmacology (Berl). 2009 May;203(4):685-91. doi: 10.1007/s00213-008-1410-6. Epub 2008 Nov 25. Psychopharmacology (Berl). 2009. PMID: 19031070 Clinical Trial.
• Single dose of mirtazapine modulates whole-brain functional connectivity during emotional narrative processing.
  Komulainen E, Glerean E, Meskanen K, Heikkilä R, Nummenmaa L, Raij TT, Lahti J, Jylhä P, Melartin T, Isometsä E, Ekelund J. Komulainen E, et al. Psychiatry Res Neuroimaging. 2017 May 30;263:61-69. doi: 10.1016/j.pscychresns.2017.03.009. Epub 2017 Mar 22. Psychiatry Res Neuroimaging. 2017. PMID: 28366871 Clinical Trial.
• A single dose of mirtazapine attenuates neural responses to self-referential processing.
  Komulainen E, Heikkilä R, Meskanen K, Raij TT, Nummenmaa L, Lahti J, Jylhä P, Melartin T, Harmer CJ, Isometsä E, Ekelund J. Komulainen E, et al. J Psychopharmacol. 2016 Jan;30(1):23-32. doi: 10.1177/0269881115616384. Epub 2015 Nov 17. J Psychopharmacol. 2016. PMID: 26577062 Clinical Trial.
• Functional atlas of emotional faces processing: a voxel-based meta-analysis of 105 functional magnetic resonance imaging studies.
  Fusar-Poli P, Placentino A, Carletti F, Landi P, Allen P, Surguladze S, Benedetti F, Abbamonte M, Gasparotti R, Barale F, Perez J, McGuire P, Politi P. Fusar-Poli P, et al. J Psychiatry Neurosci. 2009 Nov;34(6):418-32. J Psychiatry Neurosci. 2009. PMID: 19949718 Free PMC article. Review.
• The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission.
  de Boer T. de Boer T. Int Clin Psychopharmacol. 1995 Dec;10 Suppl 4:19-23. doi: 10.1097/00004850-199512004-00004. Int Clin Psychopharmacol. 1995. PMID: 8930006 Review.

Cited by

• Exploring the prediction of emotional valence and pharmacologic effect across fMRI studies of antidepressants.
  Barron DS, Salehi M, Browning M, Harmer CJ, Constable RT, Duff E. Barron DS, et al. Neuroimage Clin. 2018 Aug 11;20:407-414. doi: 10.1016/j.nicl.2018.08.016. eCollection 2018. Neuroimage Clin. 2018. PMID: 30128279 Free PMC article.
• The Effect of the 5-HT4 Agonist, Prucalopride, on a Functional Magnetic Resonance Imaging Faces Task in the Healthy Human Brain.
  de Cates AN, Martens MAG, Wright LC, Gould van Praag CD, Capitão LP, Gibson D, Cowen PJ, Harmer CJ, Murphy SE. de Cates AN, et al. Front Psychiatry. 2022 Apr 12;13:859123. doi: 10.3389/fpsyt.2022.859123. eCollection 2022. Front Psychiatry. 2022. PMID: 35492722 Free PMC article.
• Cognitive neuropsychological theory of antidepressant action: a modern-day approach to depression and its treatment.
  Godlewska BR, Harmer CJ. Godlewska BR, et al. Psychopharmacology (Berl). 2021 May;238(5):1265-1278. doi: 10.1007/s00213-019-05448-0. Epub 2020 Jan 15. Psychopharmacology (Berl). 2021. PMID: 31938879 Free PMC article. Review.
• Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease.
  Ye Z, Altena E, Nombela C, Housden CR, Maxwell H, Rittman T, Huddleston C, Rae CL, Regenthal R, Sahakian BJ, Barker RA, Robbins TW, Rowe JB. Ye Z, et al. Brain. 2014 Apr;137(Pt 4):1145-55. doi: 10.1093/brain/awu032. Epub 2014 Feb 27. Brain. 2014. PMID: 24578545 Free PMC article. Clinical Trial.
• Early changes in emotional processing as a marker of clinical response to SSRI treatment in depression.
  Godlewska BR, Browning M, Norbury R, Cowen PJ, Harmer CJ. Godlewska BR, et al. Transl Psychiatry. 2016 Nov 22;6(11):e957. doi: 10.1038/tp.2016.130. Transl Psychiatry. 2016. PMID: 27874847 Free PMC article.

References

1. 1. Arch Gen Psychiatry. 1961 Jun;4:561-71 - PubMed
2. 1. Clin Pharmacokinet. 2000 Jun;38(6):461-74 - PubMed
3. 1. Magn Reson Med. 2003 Jan;49(1):193-7 - PubMed
4. 1. J Affect Disord. 2009 Nov;118(1-3):87-93 - PubMed
5. 1. Neuroimage. 2001 Dec;14(6):1370-86 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Springer